Glyburide As Treatment Option in Decreasing Intracranial Pressure Associated with Idiopathic Intracranial Hypertension. (P2.211)
CONCLUSION: Glyburide has been shown to decrease intracranial pressure in acute ischemic strokes both in animal studies and early human clinical trials by blocking SURI-1-sodium channel receptors. This is the first time the effectiveness of Glyburide has been documented in patients with IIH. Further studies are needed to evaluate the effectiveness of Glyburide in decreasing cerebral spine fluid pressure in intracranial idiopathic hypertension.Disclosure: Dr. Ahad has nothing to disclose. Dr. Ahmed has nothing to disclose. Dr. Ahmed has nothing to disclose. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Ahad, R., Khosla, S., Ahmed, I. Tags: Headache: Therapeutics Source Type: research
GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (S7.004)
Conclusions:RP-1127 was safe but the trial did not meet the primary efficacy outcome. Among patients with large hemispheric stroke at risk for cerebral edema, RP-1127 may reduce mortality and midline shift. Further prospective study is warranted to confirm these findings.Disclosure: Dr. Sheth has nothing to disclose. Dr. Elm has received research support from Remedy. Dr. Hinson has nothing to disclose. Dr. Molyneaux has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Sze has received research support from Remedy. Dr. Ostwaldt has received research support from Remedy. Dr. Del Zoppo has received research suppor...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Sheth, K., Elm, J., Hinson, H., Molyneaux, B., Beslow, L., Sze, G., Ostwaldt, A.-C., Del Zoppo, G., Simard, J., Jacobson, S., Kimberly, W. Tags: Stroke Clinical Trials Source Type: research
GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (S7.006)
Conclusions: RP-1127 reduced neuroimaging markers of brain edema and total MMP-9 level.Disclosure: Dr. Kimberly has received research support from Remedy Pharmaceuticals, Inc. Dr. Elm has received research support from Remedy. Dr. Hinson has nothing to disclose. Dr. Molyneaux has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Sze has received research support from Remedy. Dr. Ostwaldt has received research support from Remedy. Dr. Del Zoppo has received research support from Remedy. Dr. Simard has received royalty payments from Remedy. Dr. Sheth has nothing to disclose. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kimberly, W. T., Elm, J., Hinson, H., Molyneaux, B., Beslow, L., Sze, G., Ostwaldt, A.-C., Del Zoppo, G., Simard, M., Sheth, K. Tags: Stroke Clinical Trials Source Type: research
GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (I11.006)
Conclusions:RP-1127 was safe but the trial did not meet the primary efficacy outcome. Among patients with large hemispheric stroke at risk for cerebral edema, RP-1127 may reduce mortality and midline shift. Further prospective study is warranted to confirm these findings.Disclosure: Dr. Sheth has nothing to disclose. Dr. Elm has received research support from Remedy. Dr. Hinson has nothing to disclose. Dr. Molyneaux has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Sze has received research support from Remedy. Dr. Ostwaldt has received research support from Remedy. Dr. Del Zoppo has received research suppor...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Sheth, K., Elm, J., Hinson, H., Molyneaux, B., Beslow, L., Sze, G., Ostwaldt, A.-C., Del Zoppo, G., Simard, J., Jacobson, S., Kimberly, W. Tags: Neurocritical Care and Neuroscience Crossroads: From Bench To Bedside Data Blitz Presentations Source Type: research
GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (I11.010)
Conclusions: RP-1127 reduced neuroimaging markers of brain edema and total MMP-9 level.Disclosure: Dr. Kimberly has received research support from Remedy Pharmaceuticals, Inc. Dr. Elm has received research support from Remedy. Dr. Hinson has nothing to disclose. Dr. Molyneaux has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Sze has received research support from Remedy. Dr. Ostwaldt has received research support from Remedy. Dr. Del Zoppo has received research support from Remedy. Dr. Simard has received royalty payments from Remedy. Dr. Sheth has nothing to disclose. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kimberly, W. T., Elm, J., Hinson, H., Molyneaux, B., Beslow, L., Sze, G., Ostwaldt, A.-C., Del Zoppo, G., Simard, M., Sheth, K. Tags: Neurocritical Care and Neuroscience Crossroads: From Bench To Bedside Poster Presentations Source Type: research
Pregnancy snapshot: A retrospective, observational case-control study to evaluate potential effects of maternal diabetes treatment during pregnancy on macrosomia.
CONCLUSIONS: Healthcare utilization and endocrinologist care were related to positive birth outcomes, especially with GDM. Further research into the safety and efficacy of glyburide in pregnancy is warranted. This study cannot infer causality and may not be representative of current US healthcare practice.
PMID: 26958899 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 10, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Secular trends in antihyperglycemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013
ConclusionsIn patients with chronic kidney disease, there were trends towards safer antihyperglycemic medication prescribing. A considerable number of patients, however, continue to receive medications that should be avoided. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Kristin K. Clemens, Kuan Liu, Salimah Shariff, Guntram Schernthaner, Navdeep Tangri, Amit X. Garg Tags: ORIGINAL ARTICLE Source Type: research
Diet therapy may be as effective as glyburide for treatment of mild gestational diabetes
(Source: Journal of Midwifery and Women's Health)
Source: Journal of Midwifery and Women's Health - February 9, 2016 Category: Midwifery Tags: Updates from the Literature Source Type: research
Gestational Diabetes Mellitus.
Abstract
Based on the Hyperglycemia and Adverse Pregnancy Outcome study, new universal screening recommendations and cut-offs for gestational diabetes mellitus (GDM) have been proposed. In addition to the immediate perinatal risk, GDM carries an increased risk of metabolic disease in the mother and child. Maternal obesity has even been shown to be associated with increased all-cause mortality in offspring. In addition to known risk factors, excessive gestational weight gain, increased fat consumption, a low vitamin D level, psychological stress and negative mood are risk factors for GDM. Regarding therapy,...
Source: Endocrine Development - January 30, 2016 Category: Endocrinology Authors: Spaight C, Gross J, Horsch A, Puder JJ Tags: Endocr Dev Source Type: research
The 'Old' Anti-Diabetic Agents: A Systematic Inventory.
Abstract
An array of oral agents is available for the treatment of hyperglycaemia in type 2 diabetes. This systematic inventory focuses on 'old' oral agents, including metformin, sulfonylureas (SUs), thiazolidinediones, alpha glucosidase inhibitors, and meglitinides. Twelve meta-analyses and six randomized controlled trials that used patient-relevant outcomes as primary endpoints were critically reviewed. Guidelines recommend the use of metformin or an SU as the first-line pharmacotherapeutic options. Beneficial effects of metformin have been demonstrated for 'any diabetes-related endpoint' and 'all-cause ...
Source: Endocrine Development - January 30, 2016 Category: Endocrinology Authors: Buhse S, Mühlhauser I, Lenz M Tags: Endocr Dev Source Type: research
Predicting failure of glyburide therapy in gestational diabetes
mp; A Tita (Source: Journal of Perinatology)
Source: Journal of Perinatology - January 21, 2016 Category: Perinatology & Neonatology Authors: L M HarperA V GloverJ R BiggioA Tita Source Type: research
Pharmacokinetic and Pharmacodynamic Interaction of Boswellic Acids and Andrographolide with Glyburide in Diabetic Rats: Including Its PK/PD Modeling
In conclusion, add‐on preparations containing BA or AD may increase the bioavailability of glyburide, and hence the dose should be monitored. Copyright © 2016 John Wiley & Sons, Ltd. (Source: Phytotherapy Research)
Source: Phytotherapy Research - January 13, 2016 Category: Biochemistry Authors: Sujatha Samala, Ciddi Veeresham Tags: Research Article Source Type: research
HIV Promotes NLRP3 Inflammasome Complex Activation in Murine HIV-Associated Nephropathy.
Abstract
Dysregulated growth and loss of podocytes are important features of HIV-associated nephropathy. Recently, HIV was reported to induce a new type of programed cell death, pyroptosis, in T lymphocytes through induction of Nod-like receptor protein 3 (NLRP3) inflammasome complexes. We evaluated the role of HIV in podocyte NLRP3 inflammasome formation both in vivo and in vitro. Renal cortical sections of HIV-transgenic mice (Tg26) displayed increased expression of NLRP3, ASC (a CARD protein), caspase-1, and IL-1β proteins, confirming NLRP3 inflammasome complex formation in podocytes of Tg26 mice...
Source: The American Journal of Pathology - December 10, 2015 Category: Pathology Authors: Haque S, Lan X, Wen H, Lederman R, Chawla A, Attia M, Bongu RP, Husain M, Mikulak J, Saleem MA, Popik W, Malhotra A, Chander PN, Singhal PC Tags: Am J Pathol Source Type: research
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
CONCLUSIONS: Concomitant therapy with a sulfonylurea and fibrate is associated with an often delayed increased rate of severe hypoglycemia. This article is protected by copyright. All rights reserved.
PMID: 26566262 [PubMed - as supplied by publisher] (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - November 13, 2015 Category: Drugs & Pharmacology Authors: Leonard CE, Bilker WB, Brensinger CM, Han X, Flory JH, Flockhart DA, Gagne JJ, Cardillo S, Hennessy S Tags: Clin Pharmacol Ther Source Type: research
Case Report: When an Induced Illness Looks Like a Rare Disease
We report the case of a child 4 years and 11 months old, admitted for alternance of hypo- and hyperglycemia associated with hirsutism, hypokalemia, nephrocalcinosis, and neurodevelopmental delay. All these features were compatible with Rabson-Mendenhall syndrome, a rare disorder of severe insulin resistance linked to mutations of insulin receptor. At admission, plasma insulin levels were high during hypoglycemic episodes, but c-peptide was repeatedly in the normal range. The genetic analysis of insulin receptor was negative. The story of previous hospital admissions, inconsistency between insulin and c-peptide values, and ...
Source: PEDIATRICS - November 2, 2015 Category: Pediatrics Authors: Rabbone, I., Galderisi, A., Tinti, D., Ignaccolo, M. G., Barbetti, F., Cerutti, F. Tags: Endocrinology, Diabetes Mellitus, Child Abuse and Neglect Case Report Source Type: research
